Skip to main content
. 2011 Jun 5;32(21):2678–2687. doi: 10.1093/eurheartj/ehr161

Table 1.

Baseline patient characteristics

Total (n = 2786) Primary prevention (n = 1718) Secondary prevention (n = 1068)
Clinical characteristics
 Age (years) 61 ± 13 62 ± 13 61 ± 14
 Male (%) 2192 (79) 1336 (78) 856 (80)
 Left ventricular ejection fraction (%) 33 ± 15 31 ± 14 39 ± 16
 QRS, mean (SD), ms 125 ± 34 129 ± 35 119 ± 32
 Renal clearance, mean (SD), mL/min 81 ± 37 81 ± 36 82 ± 39
 Ischaemic heart disease (%) 1800 (65) 1077 (63) 723 (68)
 History of atrial fibrillation/flutter (%) 683 (25) 447 (26) 236 (22)

Medication
 ACE-inhibitors/AT II antagonist (%) 2107 (76) 1407 (82) 700 (66)
 Aspirin (%) 1107 (40) 649 (38) 458 (43)
 Beta-blocker (%) 1513 (54) 1074 (63) 439 (41)
 Diuretics (%) 1738 (62) 1221 (71) 517 (48)
 Statins (%) 1610 (58) 1075 (63) 535 (50)

Anti-arrhythmic medicationa
 Amiodarone (%) 497 (18) 221 (13) 276 (26)
 Sotalol (%) 386 (14) 184 (11) 202 (19)

ACE, angiotensin-converting enzyme; AT, angiotensin; SD, standard deviation.

aPatients could be taking >1 anti-arrhythmic drug.